exelixis inc (EXEL:NASDAQ GS)

Executive Profile*

Background*

Mr. J. Scott Garland has been Executive Vice President and Chief Commercial Officer of Exelixis, Inc. since October 25, 2011. Mr. Garland oversees the commercial functions of marketing, sales and commercial operations, and collaborate closely with Exelixis' development and manufacturing teams to provide commercial perspective for cabozantinib development efforts across multiple oncology indications. Mr. Garland is a seasoned biotechnology and pharmaceutical industry ... veteran with over 20 years of experience commercializing new compounds and expanding franchises for existing therapies. Since 2009, Mr. Garland served as vice president of Genentech's Avastin franchise, the largest product at Genentech and one of the top five oncology products in the world. At Genentech, he served as vice president, hematology marketing and sales, overseeing the Rituxan franchise and as a director on the Tarceva franchise. Before Genentech, he spent several years at Amgen where he held several positions in sales and marketing. He also spent multiple years at Merck & Co., Inc. Mr. Garland received his MBA from Duke University's Fuqua School of Business, and his bachelor's degree from California Polytechnic University (San Luis Obispo).

Report Data Issue

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Recently Viewed
EXEL:US	$4.74 USD	-0.03

COMPETITOR COMPENSATION